Kairos Pharma, LTD.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
KAPA$0.47-6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Index to Financial Statements
| Page | |
| Report of Independent Registered Public Accounting Firm – Marcum LLP (PCAOB Firm ID: 688) | F-1 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-2 |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-5 |
| Notes to Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.